title: BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer.
abstract: Intravenous immunoglobulin (IVIg) has been used to treat autoimmune diseases and lymphoid malignancies with some therapeutic effect. In both these pathological conditions, there is an overproduction of BAFF (for "B-cell-activating factor of the TNF family"), and APRIL (for "a proliferation-inducing ligand"). The presence of antibodies (Abs) with BAFF and APRIL specificities in IVIg preparations was investigated by enzyme-linked immunosorbent assay, and Western Blot analysis. Apoptosis was measured by the annexin-V binding method, and confirmed using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling technique. Nonglycosylated recombinant BAFF, glycosylated affinity-purified BAFF, and recombinant APRIL (but not TNFalpha), were recognized by certain IgG in IVIg, and their F(ab')(2) fragments. Steric hindrance prevented the antiapoptotic effects of BAFF on B-lymphocytes. This work documents the presence of anti-BAFF and anti-APRIL Abs in IVIg. These can functionally neutralize the role of BAFF in B-cell survival. These anti-BAFF IgG might amend deleterious effects of BAFF in B-cell-mediated autoimmune diseases.
authors: Department of Immunopathology, Brest University Medical School, Brest, France.
authors: Laëtitia
authors: L
authors: Le Pottier
authors: Boutahar
authors: B
authors: Bendaoud
authors: Maryvonne
authors: M
authors: Dueymes
authors: Capucine
authors: C
authors: Daridon
authors: Pierre
authors: P
authors: Youinou
authors: Yehuda
authors: Y
authors: Shoenfeld
authors: Jacques-Olivier
authors: JO
authors: Pers
mesh_terms: D000293:Adolescent; D000941:Antigens / Q000276:immunology; D017209:Apoptosis; D015551:Autoimmunity / Q000276:immunology*; D053264:B-Cell Activating Factor / Q000276:immunology*; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology; D002478:Cells, Cultured; D002648:Child; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology* / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology* / Q000628:therapy; D011485:Protein Binding
chemical_list: D000941:Antigens; D053264:B-Cell Activating Factor; D016756:Immunoglobulins, Intravenous; C505719:TNFSF13B protein, human